Jasper Therapeutics Inc. will present at the Stifel 2025 Healthcare Conference on November 11, 2025, where the company will discuss its development of briquilimab, a novel antibody therapy targeting KIT (CD117) for mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567651-en) on November 04, 2025, and is solely responsible for the information contained therein.